Drug intelligence / Profile preview

anti-αvβ8 monoclonal antibody (Venn Therapeutics)

Development stage: Preclinical
Lead developer: Venn Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal, Intravenous, Subcutaneous

Overview

Venn Therapeutics is developing a program of monoclonal antibodies targeting the αvβ8 integrin for the treatment of solid tumors. The αvβ8 integrin is a key mediator in the activation of latent TGF-β (Transforming Growth Factor-beta) within the tumor microenvironment. By blocking this integrin, the antibodies are intended to inhibit TGF-β signaling, which is often exploited by tumors to suppress the immune system and promote growth. This therapeutic approach aims to restore anti-tumor immunity and reduce fibrosis within the tumor microenvironment. The program is currently in the preclinical stage of development.

Other names: Anti-αvβ8 monoclonal antibody programs

Targets

αVβ8 (Integrin alpha V beta 8)

Beyond the preview

Go deeper on anti-αvβ8 monoclonal antibody (Venn Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-αvβ8 monoclonal antibody (Venn Therapeutics).

Explore the full profile